Kwality Pharmaceuticals Ltd. (KPL) proudly announces the approval of its oncology oral solid dosage (OSD) product, Tamoxifen 20mg Tablet, by the South African Health Products Regulatory Authority (SAHPRA). This milestone was achieved through a successful site transfer process, emphasizing our dedication to delivering high-quality oncology treatments worldwide.
Tamoxifen 20mg is a critical therapeutic for patients battling hormone receptor-positive breast cancer. This approval reinforces our mission to enhance global access to life-saving oncology medications.
This accomplishment highlights its commitment to meeting stringent regulatory standards and ensuring the availability of effective cancer treatments in key regions.
In the meantime, Kwality Pharmaceuticals shares opened at ₹879.80, reaching a high of ₹893.80 and matching the opening as its low today. The stock has seen a significant rise over the past year, with a 52-week high of ₹961.15 and a low of ₹371.55.
